BioCentury | Apr 9, 2021
Translation in Brief

Two ways to reverse CAR T cell exhaustion; plus a ligand and its receptor in a single vector, Cleave, Amazentis and Cello

...By Danielle Golovin, Staff Writer A Stanford University team led by Crystal Mackall, co-founder of Lyell Immunopharma Inc....
...2PDE-6 – Phosphodiesterase-6 TLR7 – Toll-like receptor 7TLR8 – Toll-like receptor 8 Danielle Golovin Sprycel, dasatinib (BMS-354825) CB-5339 Stanford University Lyell Immunopharma Inc. Obsidian...
BioCentury | Mar 31, 2021
Finance

March 31 Quick Takes: Muted reception for Achilles in market debut; plus BridgeBio-Helsinn, Scribe, Outpace, OnQuality, AffaMed, Treos

...Outpace Bio Inc. raised a $30 million series A round led by Artis Ventures and Lyell Immunopharma Inc....
BioCentury | Feb 9, 2021
Management Tracks

Dynavax taps Yu to head vaccine research; plus CFO moves at Lilly, Gemini, Caribou and Lyell

...at Audentes Therapeutics Inc., which Astellas Pharma Inc. (Tokyo:4503) acquired in early 2020. Cell therapy developer Lyell Immunopharma Inc....
...Securities’ healthcare investment banking practice in the Americas. BC Staff Dynavax Technologies Corp. Eli Lilly and Co. Caribou Biosciences Inc. Lyell Immunopharma Inc....
BioCentury | Dec 18, 2020
Product Development

2021 Predictions: a BioCentury survey

...solid tumors.Several high-profile start-ups, including cell therapy company Lyell Immunopharma Inc....
BioCentury | Nov 20, 2020
Finance

SR One’s newfound freedom allows firm to increase focus on company creation

...Inc. (NASDAQ:VIR) and cancer cell therapy play Lyell Immunopharma Inc. Stephen...
BioCentury | Oct 17, 2020
Management Tracks

Merck KGaA’s Rossetti retires; plus moves at J&J, Innovent, eFFECTOR, Nautilus, Epirium and more

Luciano Rossetti will retire at year-end from Merck KGaA (Xetra:MRK) after a six-year tenure as global head of R&D for the healthcare business sector. Rossetti’s successors are Danny Bar-Zohar, who will join the organization on Nov. 1 as global head...
BioCentury | Oct 1, 2020
Finance

Sonoma tops off series A as it builds broader Treg therapy pipeline

...A round, announced Wednesday it has now raised a total of $70 million from investors including Lyell Immunopharma Inc....
...and Abbott Laboratories (NYSE:ABT) that included leadership roles in immuno-oncology and immunology drug discovery. Karen Tkach Tuzman Lyell Immunopharma Inc. Sonoma...
BioCentury | Aug 22, 2020
Translation in Brief

IPD’s synthetic bio unlocks target combos for cell therapy; plus Merck’s oral STING agonist, Surrozen’s regenerative therapy and more

...patents related to the switch technology, dubbed Co-LOCKR (Colocalization-dependent Latching Orthogonal Cage/Key pRoteins), hold equity in Lyell Immunopharma Inc....
BioCentury | Aug 12, 2020
Product Development

Aug. 11 Quick Takes: BMS hits, Genentech misses; plus JW-Lyell, CStone, Big Health

...junction cancer.JW, Lyell collaborate on T cell therapy in AsiaJW Therapeutics (Shanghai) Co. Ltd. and Lyell Immunopharma Inc. ...
...BMS-936558 (Compound #), nivolumab (Generic), Opdivo (Other) Big Health Bristol Myers Squibb Co. Genentech Inc. JW (Cayman) Therapeutics Co. Ltd. Lyell Immunopharma Inc. Neurology Insomnia...
BioCentury | Jun 19, 2020
Deals

Lyell, Pact combine T cell techs to take on solid tumors

...independent pipelines, the joint program could ultimately become both companies’ next-generation platform. The deal is Lyell Immunopharma Inc.’s...
...COVID-19 lockdown period. “This is very much a COVID-19 marriage,” Klausner said. Karen Tkach Tuzman, Associate Editor Lyell Immunopharma Inc. Pact...
Items per page:
1 - 10 of 22
BioCentury | Apr 9, 2021
Translation in Brief

Two ways to reverse CAR T cell exhaustion; plus a ligand and its receptor in a single vector, Cleave, Amazentis and Cello

...By Danielle Golovin, Staff Writer A Stanford University team led by Crystal Mackall, co-founder of Lyell Immunopharma Inc....
...2PDE-6 – Phosphodiesterase-6 TLR7 – Toll-like receptor 7TLR8 – Toll-like receptor 8 Danielle Golovin Sprycel, dasatinib (BMS-354825) CB-5339 Stanford University Lyell Immunopharma Inc. Obsidian...
BioCentury | Mar 31, 2021
Finance

March 31 Quick Takes: Muted reception for Achilles in market debut; plus BridgeBio-Helsinn, Scribe, Outpace, OnQuality, AffaMed, Treos

...Outpace Bio Inc. raised a $30 million series A round led by Artis Ventures and Lyell Immunopharma Inc....
BioCentury | Feb 9, 2021
Management Tracks

Dynavax taps Yu to head vaccine research; plus CFO moves at Lilly, Gemini, Caribou and Lyell

...at Audentes Therapeutics Inc., which Astellas Pharma Inc. (Tokyo:4503) acquired in early 2020. Cell therapy developer Lyell Immunopharma Inc....
...Securities’ healthcare investment banking practice in the Americas. BC Staff Dynavax Technologies Corp. Eli Lilly and Co. Caribou Biosciences Inc. Lyell Immunopharma Inc....
BioCentury | Dec 18, 2020
Product Development

2021 Predictions: a BioCentury survey

...solid tumors.Several high-profile start-ups, including cell therapy company Lyell Immunopharma Inc....
BioCentury | Nov 20, 2020
Finance

SR One’s newfound freedom allows firm to increase focus on company creation

...Inc. (NASDAQ:VIR) and cancer cell therapy play Lyell Immunopharma Inc. Stephen...
BioCentury | Oct 17, 2020
Management Tracks

Merck KGaA’s Rossetti retires; plus moves at J&J, Innovent, eFFECTOR, Nautilus, Epirium and more

Luciano Rossetti will retire at year-end from Merck KGaA (Xetra:MRK) after a six-year tenure as global head of R&D for the healthcare business sector. Rossetti’s successors are Danny Bar-Zohar, who will join the organization on Nov. 1 as global head...
BioCentury | Oct 1, 2020
Finance

Sonoma tops off series A as it builds broader Treg therapy pipeline

...A round, announced Wednesday it has now raised a total of $70 million from investors including Lyell Immunopharma Inc....
...and Abbott Laboratories (NYSE:ABT) that included leadership roles in immuno-oncology and immunology drug discovery. Karen Tkach Tuzman Lyell Immunopharma Inc. Sonoma...
BioCentury | Aug 22, 2020
Translation in Brief

IPD’s synthetic bio unlocks target combos for cell therapy; plus Merck’s oral STING agonist, Surrozen’s regenerative therapy and more

...patents related to the switch technology, dubbed Co-LOCKR (Colocalization-dependent Latching Orthogonal Cage/Key pRoteins), hold equity in Lyell Immunopharma Inc....
BioCentury | Aug 12, 2020
Product Development

Aug. 11 Quick Takes: BMS hits, Genentech misses; plus JW-Lyell, CStone, Big Health

...junction cancer.JW, Lyell collaborate on T cell therapy in AsiaJW Therapeutics (Shanghai) Co. Ltd. and Lyell Immunopharma Inc. ...
...BMS-936558 (Compound #), nivolumab (Generic), Opdivo (Other) Big Health Bristol Myers Squibb Co. Genentech Inc. JW (Cayman) Therapeutics Co. Ltd. Lyell Immunopharma Inc. Neurology Insomnia...
BioCentury | Jun 19, 2020
Deals

Lyell, Pact combine T cell techs to take on solid tumors

...independent pipelines, the joint program could ultimately become both companies’ next-generation platform. The deal is Lyell Immunopharma Inc.’s...
...COVID-19 lockdown period. “This is very much a COVID-19 marriage,” Klausner said. Karen Tkach Tuzman, Associate Editor Lyell Immunopharma Inc. Pact...
Items per page:
1 - 10 of 22